<DOC>
	<DOCNO>NCT01125189</DOCNO>
	<brief_summary>To establish least 1 dose daclatasvir combine standard care ( pegylated interferon ribavirin ) safe well tolerate demonstrates extend rapid virologic response rate least 35 % great placebo .</brief_summary>
	<brief_title>Study Daclatasvir ( BMS-790052 ) Add-on Standard Care Treatment- naïve Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients chronically infect hepatitis C virus ( HCV ) genotype 1 4 HCV RNA viral load ≥100,000 IU/mL No previous exposure interferon , pegIFNα , RBV Results liver biopsy demonstrate absence cirrhosis obtain ≤24 month prior randomization . Compensated cirrhotics Hepatitis C virus genotype 1 infection eligible , cap 10 % randomize study population ( biopsy time period prior randomization ) Findings ultrasound , compute tomography scan , magnetic resonance image 12 month prior randomization demonstrate evidence hepatocellular carcinoma Body mass index 18 35 kg/m^2 Positive hepatitis B HIV1/HIV2 antibody screen Evidence medical condition associate chronic liver disease HCV Evidence decompensated cirrhosis base radiologic criterion biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>